Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06563856 · ClinicalTrials.gov registry record · Phase 1

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

A Phase 1 study of Bioavailability and Bioequivalence, sponsored by Amgen.

Completed
Registry status
Phase 1
Development phase
37
Enrollment target
1
Study location

NCT06563856: Completed Phase 1 study of Bioavailability and Bioequivalence, sponsored by Amgen.

NCT06563856 is a Phase 1 study of Bioavailability and Bioequivalence that has completed, run by Amgen. The registered enrollment target is 37 participants, roughly in line with the 34-participant average among 8 other Bioavailability trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06563856, a Phase 1 study of Bioavailability and Bioequivalence, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.

Conditions Studied

Bioavailability Bioequivalence

Interventions

  • DRUG TEPEZZA
  • DRUG EDP

Study Locations (1)

Nevada

  • PPD Development - Las Vegas

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2020-09-22
Est. Completion 2021-05-27
Phase Phase 1
Amgen

558 total trials

What the finished NCT06563856 record still lists

NCT06563856 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, roughly in line with the 34-participant average among 8 other Bioavailability trials with a reported enrollment target.

The record links to 2 conditions, with Bioavailability appearing as the primary indexed condition, and to 2 interventions - of which TEPEZZA is the first listed.

NCT06563856 reports a single indexed study location in Nevada.

Frequently Asked Questions

What is clinical trial NCT06563856 about?

NCT06563856 is a clinical study titled "A Study of TEPEZZA Subcutaneous Administration in Healthy Adults". The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.

What is the current status of trial NCT06563856?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2020-09-22. Estimated completion is 2021-05-27.

What conditions does trial NCT06563856 study?

This clinical trial studies the following conditions: Bioavailability, Bioequivalence.

What interventions are being tested in trial NCT06563856?

The interventions under investigation include: TEPEZZA (DRUG), EDP (DRUG).

Who is sponsoring clinical trial NCT06563856?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06563856 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bioavailability

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06563856's enrollment target sits among peer trials

37 4th of 8 higher than 5 of 8 other Bioavailability trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bioavailability trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06563856, the US trial registry maintained by the National Library of Medicine. NCT06563856 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.